(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it has signed a non-binding letter of intent (LOI) with ProMab Biotechnologies to develop cell based therapies. PR-12222016.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the quarter ended October 31, 2016. PR-12132016.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, intends to meet a selection of Big Pharma and Big Biotech companies during the Annual JP Morgan Conference week in San Francisco during January 9-12, 2017. In addition, Helix […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announce that it presented topline data from its phase I/II dose escalation study of immunoconjugate LDOS47 as a monotherapy in non-squamous non-small cell lung cancer patients at the 17th […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after reviewing safety data from the Phase I/II study of L-DOS47 in nonsquamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company’s poster entitled: Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients has been […]
Presentation details are as follows: #4455 Poster Session on December 6, 2016 between 2:30 – 3:45PM (Hall B) Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous nonsmall cell lung cancer patients Author(s): Rodryg Ramlau, Dariusz Kowalski, Cezary Szczylik, Aleksandra Szczęsna, Elzbieta Wiatr, Steve Demas, Heman Chao, Kazimierz Roszkowski-Sliz Helix-PR-11172016.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2016. Helix-PR-10312016.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company’s Chief Executive Officer, Dr. Sven Rohmann, will present a corporate overview at the National Investment Banking Association (“NIBA”) conference on Thursday […]
CAR-T cells harboring a camelid single domain antibody as a targeting agent to CEACAM6 antigen in pancreatic cancer